- Dec 1, 2020
NCT04302324: Phase 2: Daratumumab, Clarithromycin, Pomalidomide And Dex RRMM - D-ClaPd
D-ClaPd NCT04302324: Phase 2: A Phase II Study of Daratumumab, Clarithromycin, Pomalidomide And Dexamethasone (D-ClaPd) In Multiple...
66
- Dec 1, 2020
NCT04445701: Phase 1/2: Study of AO-176 as Monotherapy and in Combination With Bortezomib/Dex RRMM
NCT04445701: Phase 1/2: Study of AO-176 as Monotherapy and in Combination With Bortezomib/Dexamethasone in Relapsed/Refractory Multiple...
134
- Dec 1, 2020
NCT04513639: Phase 2/3: The Relapse From MRD Negativity as Indication for Treatment (REMNANT) Study
NCT04513639: Phase 2/3: The Relapse From MRD Negativity as Indication for Treatment (REMNANT) Study Dara-Kd The Relapse From MRD...
326
- Dec 1, 2020
NCT04270409: Phase 3 - Isatuximab in Combination With Lenalidomide and Dex High-risk SMM (ITHACA)
(ITHACA) High-risk Smoldering Multiple Myeloma NCT04270409 NCT04270409: Phase 3 - Isatuximab in Combination With Lenalidomide and...
380
- Dec 1, 2020
AMaRC 19-02 - BelaCarD - Phase I/II - Study of combination belantamab maf, carfilzomib, Dex RRMM
BelaCarD Study AMaRC: (PHASE I/II) BELACARD FOR RELAPSED REFRACTORY MULTIPLE MYELOMA A phase I/II single arm study on the efficacy of...
135
- Dec 1, 2020
NCT04430894: Phase 2: KRDI in Transplant-Eligible MM
NCT04430894: Phase 2: KRDI in Transplant-Eligible MM KRDI in Transplant-Eligible MM This research study is testing the efficacy of an...
105